AbbVie’s Humira Maintains Market Dominance Amid Biosimilar Launches: Report

AbbVie’s blockbuster antibody Humira (adalimumab) has ceded only 2% of its massive market share to the five biosimilars that hit U.S. shelves last year, according to Samsung Bioepis’ 4th Biosimilar Market Report.